Tasos Konidaris - 03 Mar 2023 Form 4 Insider Report for Amneal Pharmaceuticals, Inc. (AMRX)

Role: Executive Vice President & CFO
Signature: /s/ Denis Butkovic, Attorney-in-Fact
Issuer symbol: AMRX
Transactions as of: 03 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 07 Mar 2023, 17:00:52 UTC
Previous filing: 03 Mar 2023
Next filing: 14 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMRX	Class A Common Stock	Options Exercise		+45,289	+18%		293,121	03 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMRX	Restricted Stock Units	Options Exercise	$0	-45,289	-25%	$0.000000	135,870	03 Mar 2023	Class A Common Stock	45,289		Direct	F2, F3
transaction	AMRX	Restricted Stock Units	Award	$0	+229,358		$0.000000	229,358	03 Mar 2023	Class A Common Stock	229,358		Direct	F2, F4
transaction	AMRX	Performance-Based Restricted Stock Units	Award	$0	+458,716		$0.000000	458,716	03 Mar 2023	Class A Common Stock	458,716		Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's Class A Common Stock awarded to the reporting person in connection with the vesting of restricted stock units.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3	On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
F4	The restricted stock units vest in four equal annual installments beginning on March 3, 2024.
F5	Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F6	Represents a performance-based restricted stock unit grant of 229,358 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period.